(Q35844077)

10 August 2017

1 reference

title

The role of retroperitoneal lymph node dissection in the management of testicular cancer (English)

1 reference

10 August 2017

0 references

Andrew J Stephenson

1

1 reference

10 August 2017

Joel Sheinfeld

series ordinal

2

1 reference

10 August 2017

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

225-33; discussion 234-5

1 reference

10 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Nonseminomatous germ cell tumors of the testis: current concepts and controversies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Distribution of nodal metastases in nonseminomatous testis cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical stage II nonseminomatous germinal testis tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late relapse of testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Update on late relapse of germ cell tumor: a clinical and molecular analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Autopsy findings in 154 patients with germ cell tumors of the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Risks of the uncontrolled retroperitoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Orchiectomy alone in clinical stage I nonseminomatous testis cancer: a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

No Adjuvant Chemotherapy in Selected Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumors of the Testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Stage II nonseminomatous testicular cancer: a 10-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Prognostic factors in nonseminomatous testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late relapse of clinical stage I testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

The growing teratoma syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Testicular germ-cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late toxicity following curative treatment of testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Laparoscopic retroperitoneal lymph node dissection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Laparoscopic retroperitoneal lymph node dissection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Adjuvant Chemotherapy in Resected Stage-II Nonseminomatous Germ Cell Tumors of Testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Cytoreductive Surgery for Metastatic Testis Cancer: Considerations of Timing and Extent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Chemotherapy for teratoma with malignant transformation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late recurrence of testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late recurrence of mature teratoma in nonseminomatous testicular tumors after PVB chemotherapy and surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Computerized tomography: how accurate for abdominal staging of testis tumors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Non-seminomatous testicular cancer clinical stage I: prediction of outcome by histopathological parameters. A multivariate analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Surgical salvage of chemorefractory germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

The treatment of advanced metastatic seminoma: experience in 55 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

Pilot Study to Evaluate Impact of a Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.04.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2004.04.029

1 reference

10 August 2017

1 reference